Literature DB >> 17627519

Therapeutic targets in the ARF tumor suppressor pathway.

Anthony J Saporita1, Leonard B Maggi, Anthony J Apicelli, Jason D Weber.   

Abstract

One of the outstanding fundamental questions in cancer cell biology concerns how cells coordinate cellular growth (or macromolecular synthesis) with cell cycle progression and mitosis. Intuitively, rapidly dividing cells must have some control over these processes; otherwise cells would continue to shrink in volume with every passing cycle, similar to the cytoreductive divisions seen in the very early stages of embryogenesis. The problem is easily solved in unicellular organisms, such as yeast, as their growth rates are entirely dependent on nutrient availability. Multicellular organisms such as mammals, however, must have acquired additional levels of control, as nutrient availability is seldom an issue and the organism has a prodigious capacity to store necessary metabolites in the form of glycogen, lipids, and protein. Furthermore, the specific needs and specialized architecture of tissues must constrain growth for growth's sake; if not, the necessary function of the organ could be lost. While certainly a myriad of mechanisms for preventing this exist via initiating cell death (e.g. apoptosis, autophagy, necrosis), these all depend on some external cue, such as death signals, hypoxia, lack of nutrients or survival signals. However there must also be some cell autonomous method for surveying against inappropriate growth signals (such as oncogenic stress) that occur in a stochastic fashion, possibly as a result of random mutations. The ARF tumor suppressor seems to fulfill that role, as its expression is near undetectable in normal tissues, yet is potently induced by oncogenic stress (such as overexpression of oncogenic Ras or myc). As a result of induced expression of ARF, the tumor suppressor protein p53 is stabilized and promotes cell cycle arrest. Mutations or epigenetic alterations of the INK4a/Arf locus are second only to p53 mutations in cancer cells, and in some cancers, alterations in both Arf and p53 observed, suggesting that these two tumor suppressors act coordinately to prevent unwarranted cell growth and proliferation. The aim of this review is to characterize the current knowledge in the field about both p53-dependent and independent functions of ARF as well as to summarize the present models for how ARF might control rates of cell proliferation and/or macromolecular synthesis. We will discuss potential therapeutic targets in the ARF pathway, and some preliminary attempts at enhancing or restoring the activity of this important tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627519      PMCID: PMC2859726          DOI: 10.2174/092986707781058869

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  195 in total

1.  Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability.

Authors:  Hiroyuki Yamamoto; Yongfen Min; Fumio Itoh; Arisa Imsumran; Shina Horiuchi; Mio Yoshida; Shouhei Iku; Hiroshi Fukushima; Kohzoh Imai
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

2.  Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.

Authors:  T Watanabe; M Nakamura; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

3.  p14ARF deletion and methylation in genetic pathways to glioblastomas.

Authors:  M Nakamura; T Watanabe; U Klangby; C Asker; K Wiman; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  2001-04       Impact factor: 6.508

4.  Major nucleolar proteins shuttle between nucleus and cytoplasm.

Authors:  R A Borer; C F Lehner; H M Eppenberger; E A Nigg
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

5.  Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.

Authors:  M Simon; T W Park; G Köster; R Mahlberg; M Hackenbroch; J Boström; T Löning; J Schramm
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

6.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

7.  High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma.

Authors:  Kazuya Sakuma; Ja-Mun Chong; Makoto Sudo; Tetsuo Ushiku; Yoko Inoue; Junji Shibahara; Hiroshi Uozaki; Hideo Nagai; Masashi Fukayama
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

8.  CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer.

Authors:  Marina I Gutiérrez; Abdul K Siraj; Hussein Khaled; Natalie Koon; Wa'el El-Rifai; Kishor Bhatia
Journal:  Mod Pathol       Date:  2004-10       Impact factor: 7.842

9.  Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes.

Authors:  Olivier Ayrault; Laetitia Andrique; Christian-Jacques Larsen; Paule Seite
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

10.  Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.

Authors:  Y Kawada; M Nakamura; E Ishida; K Shimada; E Oosterwijk; H Uemura; Y Hirao; K S Chul; N Konishi
Journal:  Jpn J Cancer Res       Date:  2001-12
View more
  22 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

2.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  The ARFul truth about melanoma susceptibility genes.

Authors:  Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2007-08-15       Impact factor: 4.693

4.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

5.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

Review 6.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Authors:  Stanley Lipkowitz; Allan M Weissman
Journal:  Nat Rev Cancer       Date:  2011-08-24       Impact factor: 60.716

7.  Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.

Authors:  Delin Chen; Jing Shan; Wei-Guo Zhu; Jun Qin; Wei Gu
Journal:  Nature       Date:  2010-03-07       Impact factor: 49.962

Review 8.  Transcription factors that interact with p53 and Mdm2.

Authors:  Kazushi Inoue; Elizabeth A Fry; Donna P Frazier
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

9.  Nrk2b-mediated NAD+ production regulates cell adhesion and is required for muscle morphogenesis in vivo: Nrk2b and NAD+ in muscle morphogenesis.

Authors:  Michelle F Goody; Meghan W Kelly; Kevin N Lessard; Andre Khalil; Clarissa A Henry
Journal:  Dev Biol       Date:  2010-06-08       Impact factor: 3.582

10.  Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Teneille Walker; Hossein Hamed; Elaine Studer; Martin Graf; Mohamed Rahmani; Seema Gupta; Philip B Hylemon; Paul B Fisher; Steven Grant; Paul Dent
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.